Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

One-Compartment Open Model for Extravascular Administration: First-Order Absorption Model01:15

One-Compartment Open Model for Extravascular Administration: First-Order Absorption Model

310
The first-order absorption model for extravascular administration describes the rate at which a drug is absorbed and eliminated, following the principles of first-order kinetics. This model is vital as it provides a mathematical representation of drug behavior within the body. It also allows for the prediction and interpretation of drug absorption and elimination based on the rate of change in drug concentration over time. This model can be visualized as a plasma concentration-time profile...
310
One-Compartment Open Model for Extravascular Administration: Zero-Order Absorption Model01:12

One-Compartment Open Model for Extravascular Administration: Zero-Order Absorption Model

179
Extravascular administration, such as oral or intramuscular routes, is a non-invasive drug delivery method, often preferred for ease and patient compliance. A key factor here is absorption, which dictates how quickly and effectively the drug enters the bloodstream from the administration site. Absorption follows either zero-order or first-order kinetics.
Zero-order absorption maintains a steady rate irrespective of the amount of drug left to be absorbed, making it a constant process. In the...
179
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance01:07

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance

88
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
88
Pharmacokinetic Models: Overview01:20

Pharmacokinetic Models: Overview

1.2K
Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
1.2K
One-Compartment Open Model for IV Bolus Administration: General Considerations01:19

One-Compartment Open Model for IV Bolus Administration: General Considerations

333
The one-compartment model is a pharmacokinetic tool that models the body as a single, uniform compartment, facilitating the understanding of drug distribution and elimination. This model is particularly beneficial for intravenous (IV) bolus administration, where the drug rapidly circulates throughout the body.
The drug's presence in the body is defined by an equation representing the difference between the rates of drug entry and exit. Key parameters—elimination rate constant,...
333
Factors Influencing Drug Absorption: Drug Dissolution01:27

Factors Influencing Drug Absorption: Drug Dissolution

734
The pharmacokinetic journey of drugs from solid oral dosage forms into systemic circulation is multifaceted. It begins with disintegration, a prerequisite ensuring a solid dosage form's subdivision into minute particles. Dissolution occurs next as these granulated entities solubilize in gastrointestinal fluids. This solubilization is crucial for the succeeding stage, permeation, which describes the traversal of the drug across the intestinal membrane and its subsequent entry into the blood...
734

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lexical Frequency Within Grammatical Bounds: Phonological Default and Inflection-Class Conditioning in Greek Nominal Stress.

Language and speech·2026
Same author

The top-down Physiologically Based Finite Time Pharmacokinetic (PBFTPK) models open a new avenue for early drug development.

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences·2026
Same author

Assessing the Potential of Generative Artificial Intelligence Models to Assist Experts in the Development of Pharmacokinetic Models.

Advanced pharmaceutical bulletin·2025
Same author

In-silico structural and functional analysis of nonsynonymous single nucleotide polymorphisms in human <i>FOLH1</i> gene.

In silico pharmacology·2025
Same author

FDA and EMA Oversight of Disruptive Science on Application of Finite Absorption Time (F.A.T.) Concept in Oral Drug Absorption: Time for Scientific and Regulatory Changes.

Pharmaceutics·2024
Same author

Architectural design of national evidence based medicine information system based on electronic health record.

Technology and health care : official journal of the European Society for Engineering and Medicine·2024

Related Experiment Video

Updated: Sep 19, 2025

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment
08:59

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment

Published on: December 3, 2020

8.1K

The Finite Absorption Time Concept Guiding Model Informed Drug & Generics Development in Clinical Pharmacology.

Panos Macheras1,2, Athanasios A Tsekouras3,4, Sergio Sánchez-Herrero5,6

  • 1Faculty of Pharmacy, National and Kapodistrian University of Athens, Athens, Greece. macheras@pharm.uoa.gr.

Pharmaceutical Research
|June 5, 2025
PubMed
Summary

The Finite Absorption Time (F.A.T.) concept offers improved accuracy in pharmacokinetic analysis for drug and generic development. This approach enhances drug assessment and guides regulatory strategy.

Keywords:
BioequivalenceFinite absorption timeIVIVCOral drugsPharmacokineticsPhysiologically based finite time pharmacokinetic models

More Related Videos

Visualizing and Quantifying Pharmaceutical Compounds within Skin using Coherent Raman Scattering Imaging
11:07

Visualizing and Quantifying Pharmaceutical Compounds within Skin using Coherent Raman Scattering Imaging

Published on: November 24, 2021

2.9K
Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
10:44

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Published on: March 28, 2017

10.0K

Related Experiment Videos

Last Updated: Sep 19, 2025

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment
08:59

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment

Published on: December 3, 2020

8.1K
Visualizing and Quantifying Pharmaceutical Compounds within Skin using Coherent Raman Scattering Imaging
11:07

Visualizing and Quantifying Pharmaceutical Compounds within Skin using Coherent Raman Scattering Imaging

Published on: November 24, 2021

2.9K
Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
10:44

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Published on: March 28, 2017

10.0K

Area of Science:

  • Pharmacokinetics
  • Drug Development
  • Regulatory Science

Background:

  • Traditional pharmacokinetic models may lack precision in certain absorption scenarios.
  • The Finite Absorption Time (F.A.T.) concept offers a novel approach to analyzing drug absorption.
  • Evaluating existing drug development and generic assessment frameworks is crucial.

Purpose of the Study:

  • To demonstrate the impact of incorporating the Finite Absorption Time (F.A.T.) concept into drug development.
  • To explore the implications for generic drug development and assessment.
  • To examine the associated regulatory considerations.

Main Methods:

  • Reanalyzing existing pharmacokinetic data.
  • Utilizing models specifically based on the Finite Absorption Time (F.A.T.) principles.
  • Comparing novel F.A.T.-based metrics with traditional absorption metrics.

Main Results:

  • Absorption metrics derived from F.A.T. models show superior accuracy compared to older methods.
  • The F.A.T. approach provides a more refined assessment of drug absorption characteristics.
  • Distinct advantages were observed in the analysis of pharmacokinetic data using F.A.T. models.

Conclusions:

  • The F.A.T. concept and its associated methodologies are applicable across all stages of drug and generic development.
  • These approaches can inform strategic adjustments in drug development.
  • The findings suggest potential modifications to the regulatory framework for drug assessment.